Doximity (DOCS) Q4 2026 Earnings Transcript

Doximity reported Q4 revenue of $145 million, up 5% year over year, and full-year revenue of $645 million, up 13%, while free cash flow hit a record $107 million for the quarter and $317 million for the year. The company highlighted rapid AI adoption, including 800,000 quarterly active prescribers, 140 health systems using its clinical AI suite, and initial AI search deals, but guided to only $151 million-$152 million in Q1 revenue and $664 million-$676 million for the year as AI monetization ramps later. Margin pressure from AI compute costs and softer HCP pharma ad demand temper the outlook, though buybacks remained strong at $432 million for the year.

Analysis

DOCS is at an inflection where usage is scaling faster than monetization, and that matters more than the headline guide. The market is likely underestimating how quickly the clinical workflow layer can become the wedge for a second revenue stream: once doctors are entrenched in the AI assistant, pharma spend can piggyback on intent data rather than fight for static impressions. That creates a flywheel, but it also means the near-term P&L is intentionally being sacrificed to prove the product moat before the commercialization curve is visible.

The key second-order effect is margin structure. AI compute is not just a gross margin headwind; it is a signal that the company is shifting from a high-opex, low-inference platform to a usage-based AI utility, which should make investors re-rate the business on FCF durability rather than GAAP margin expansion. The risk is that a softer pharma budget environment could delay the AI revenue unlock just long enough for the market to anchor on slower growth and lower margins, even if engagement keeps compounding underneath.

Consensus is probably missing how advantaged DOCS is in regulated AI distribution versus generic health AI vendors. Hospitals and prescribers already trust the identity layer, permissions layer, and workflow layer; competitors may have better models, but they do not have embedded access. That said, the market is also likely underpricing SBC dilution and the possibility that shorter-duration contracts become the new normal, capping near-term visibility even as total addressable spend expands over the next 12-24 months.

Key Decisions for Investors

• Buy DOCS on a pullback into the next 1-2 weeks; use a 6-12 month horizon. Risk/reward favors upside if AI monetization ramps in the back half, but position size should reflect near-term multiple compression from margin dilution and slower guide growth.
• Pair trade: long DOCS / short a premium healthcare ad-tech or digital marketing name with lower AI differentiation over the next 3-6 months. Thesis: DOCS owns the regulated workflow layer, while peers are more exposed to budget softness without a comparable product catalyst.
• Sell out-of-the-money DOCS puts 1-2 quarters out if implied vol stays elevated. The stock looks supported by FCF and buybacks, while the market is likely overpricing the probability of a downside break from short-term guide conservatism.
• Avoid chasing the upside in the next few weeks; wait for confirmation that AI search revenue is appearing in reported bookings before adding aggressively. The setup improves materially once the market gets actual monetization data rather than just usage metrics.
• For event-driven traders: consider a DOCS call spread 6-9 months out to express upside from AI commercialization while limiting premium bleed if regulatory review delays revenue recognition.